Cargando…
New and emerging biologic therapies for moderate-to-severe plaque psoriasis: mechanistic rationales and recent clinical data for IL-17 and IL-23 inhibitors
The development of effective and well-tolerated biologic therapies has advanced the management of psoriasis by enabling clinicians to treat underlying disease mechanisms. Biologics approved for the treatment of moderate-to-severe psoriasis include three tumor necrosis factor alpha inhibitors and an...
Autores principales: | Gaspari, Anthony A, Tyring, Stephen |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Blackwell Publishing Ltd
2015
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4657465/ https://www.ncbi.nlm.nih.gov/pubmed/26201310 http://dx.doi.org/10.1111/dth.12251 |
Ejemplares similares
-
A Review of Biologic Therapies Targeting IL-23 and IL-17 for Use in Moderate-to-Severe Plaque Psoriasis
por: Campa, Molly, et al.
Publicado: (2015) -
Erratum to: A Review of Biologic Therapies Targeting IL-23 and IL-17 for Use in Moderate-to-Severe Plaque Psoriasis
por: Campa, Molly, et al.
Publicado: (2016) -
Serum Levels of TNF-α, IL-12/23p40, and IL-17 in Plaque Psoriasis and Their Correlation with Disease Severity
por: Kyriakou, Aikaterini, et al.
Publicado: (2014) -
The role of IL‐23 and the IL‐23/T(H)17 immune axis in the pathogenesis and treatment of psoriasis
por: Girolomoni, G., et al.
Publicado: (2017) -
Role of IL-17 in plaque psoriasis: therapeutic potential of ixekizumab
por: Hanley, Tessa L, et al.
Publicado: (2017)